October 2007 Fingertip Formulary Insights™
Key Findings
- Overall tier trend: For tier 1 and tier 2 availability overall, there were no consistent trends across the drug classes examined. We were unable to conclude that either commercial plans or Medicare plans had broader coverage as a general rule.
- Statins/PPIs: Medicare plans showed important differences in formulary access coverage for statins and PPIs. The statins demonstrated overall formulary access coverage on tiers 1 and 2 that was approximately 14% higher for Medicare covered lives as compared to commercial lives. Likewise, PPIs were favored for Medicare on 11% more lives than commercial plans.
- No differences: The differences in coverage for the ARBs and osteoporosis were small.
- ED: As expected, erectile dysfunction had significantly greater coverage in commercial plan lives (15% of lives) versus Medicare (2% of lives), although overall coverage was limited.
Printable version (PDF 163KB)
Archives
December 2007: Lack of Impact from Two Key Generics in the Anti-depressant Formulary Market
October 2007: Formulary Position Differences between Commercial and Medicare Plans
September 2007: Impact of Patent Loss for Zocor on the Statin Marketplace
- Intro
- Formulary Access
- Trend Analysis
- Prior Authorization
- Quantity Limits
- Step Therapy
- Strategic Implications
Formulary Access
